Three meetings to discover the future

Three meetings to talk about pharmaceutical industry innovation, exchange ideas and perspectives about the future of manufacture inside the Open House.

Each meeting takes place October 18-19-20, from 2.30 to 4.30 p.m.


Day 18 & 19: Marco Silvestri – Docent Researcher at SUPSI and Assistant Professor at Parma University

Day 19 & 20: Gianluigi Ferrari –Associate Professor at Università degli studi di Parma


Which challenges the Industry 4.0 hurled to the pharmaceutical industry?

Smart Factory, digitalization, innovation of productive processes, computerization, Robotics Collaborative and 3D printer use. Focusing on those themes is necessary to see last years changes that seems to form a new industrial revolution.

We will focus especially on the world of robotics. Technological evolution will increasingly require qualified and skilled workers capable of managing new machines that will enter the production chain. Technology is not sufficient for development, it must be followed by a reorganization of human resources.


Subscribe for this workshop


Day 18,19 & 20: Gian Paolo Baranzoni – ICT & Validation Consultant in regulated environments (Pharmaceutical, Medical Devices, Health Care), ICT Transformation, ICT Governance.


Serialization of pharmaceutical products is still a relevant topic concerning pharmaceutical market due to the need to track and trace drugs with a univocal code, in order to oppose forgery and guarantee the safety of each product throughout all the production and distribution chain.

Traceability is a solid topic but still full of uncertainty that must be clarified in order to implement and adapt efficiently different laws into productive processes.


Subscribe for this workshop


Day 18,19 & 20: Sandro De CarisComputer Validation, Compliance GxP Consultant , Risk Management and Process Analytical Technology. 


Pharmaceutical companies and Life Sciences world regulations are always increasing: production levels, the country where production takes place and which the products are allocated to.
For instance, an Italian company producing for local and foreign market might be exposed to many different regulations, both European and international, and can be controlled by more than one inspection organ. EMA (European Medicines Agency) for Europe and FDA (Food and Drug Administration) for the United States.
National organs in each European country apply regulation: in Italy we have the Italian Drug Agency (AIFA).
A topic of great interest for pharmaceutical companies is Data Integrity.
The new guidelines do not change the regulation system but accentuate attention to those data generated and stored by pharmaceutical companies during production, and require both different management procedures (at the expense of the pharmaceutical company) and functional aspects of control systems (at the expense of suppliers).


Subscribe for this workshop